William Blair Brokers Decrease Earnings Estimates for NAMS

NewAmsterdam Pharma (NASDAQ:NAMS) – Analysts at William Blair reduced their Q1 2025 EPS estimates for NewAmsterdam Pharma in a research note issued to investors on Wednesday, February 26th. William Blair analyst M. Phipps now anticipates that the company will post earnings of ($0.51) per share for the quarter, down from their prior forecast of ($0.49). The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.75) per share. William Blair also issued estimates for NewAmsterdam Pharma’s Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.55) EPS, FY2025 earnings at ($2.11) EPS, Q1 2026 earnings at ($0.54) EPS, Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.56) EPS, FY2026 earnings at ($2.18) EPS, FY2027 earnings at ($2.49) EPS and FY2028 earnings at ($1.83) EPS.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The firm had revenue of $12.77 million during the quarter, compared to analyst estimates of $3.30 million.

A number of other brokerages also recently issued reports on NAMS. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. HC Wainwright restated a “buy” rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Scotiabank upped their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a report on Thursday, February 27th. Finally, Needham & Company LLC cut their target price on NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, NewAmsterdam Pharma presently has a consensus rating of “Buy” and an average price target of $43.80.

NewAmsterdam Pharma Stock Up 6.1 %

Shares of NAMS opened at $21.50 on Monday. NewAmsterdam Pharma has a 52-week low of $15.19 and a 52-week high of $27.29. The stock has a market cap of $1.99 billion, a PE ratio of -8.27 and a beta of -0.06. The firm’s fifty day moving average is $22.35 and its two-hundred day moving average is $20.39.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of NAMS. Deerfield Management Company L.P. Series C lifted its holdings in NewAmsterdam Pharma by 378.4% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company’s stock worth $110,879,000 after buying an additional 3,412,590 shares during the last quarter. Frazier Life Sciences Management L.P. increased its stake in NewAmsterdam Pharma by 23.8% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company’s stock valued at $409,052,000 after purchasing an additional 3,061,224 shares during the last quarter. Jennison Associates LLC raised its holdings in NewAmsterdam Pharma by 291.9% during the fourth quarter. Jennison Associates LLC now owns 3,998,541 shares of the company’s stock worth $102,763,000 after purchasing an additional 2,978,263 shares in the last quarter. Wellington Management Group LLP grew its position in shares of NewAmsterdam Pharma by 2,410.4% in the 4th quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company’s stock valued at $59,499,000 after buying an additional 2,222,900 shares during the last quarter. Finally, Capital International Investors acquired a new stake in NewAmsterdam Pharma during the 4th quarter worth $53,007,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at NewAmsterdam Pharma

In related news, major shareholder Nap B.V. Forgrowth sold 29,846 shares of the business’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $25.54, for a total transaction of $762,266.84. Following the completion of the transaction, the insider now directly owns 10,656,172 shares of the company’s stock, valued at $272,158,632.88. The trade was a 0.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 404,927 shares of company stock worth $10,390,787 over the last ninety days. Company insiders own 19.50% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.